MedTrace Logo

The Effect of Exenatide on Fasting Bile Acids

NCT04303819 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2020-06-11

No results posted yet for this study

Summary

Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were compared before and after exenatide treatment and correlation analysis between changes of FTBAs and glycemic parameters.

Conditions

  • Type 2 Diabetes Mellitus in Obese

Interventions

DRUG

Exenatide treatment

12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.

Sponsors & Collaborators

  • Beijing Chao Yang Hospital

    lead OTHER

Principal Investigators

  • Boyu Li, PHD · Beijing Chao Yang Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-05
Primary Completion
2020-01-28
Completion
2020-01-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04303819 on ClinicalTrials.gov